GENZYME THERAPEUTICS LIMITED
Get an alert when GENZYME THERAPEUTICS LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2027-01-14 (in 8mo)
Last made up 2025-12-31
Watchouts
Cash
—
Latest balance sheet
Net assets
£47M
0% vs 2023
Employees
—
Average over period
Profit before tax
£0
Period ending 2024-12-31
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Material uncertainty over going concern
As the company is no longer trading and the Directors intend to liquidate the company following the settlement of remaining net assets at a future date yet to be determined, they have prepared the financial statements on a basis other than going concern.
Net assets
2-year trend · vs Industrials median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £0 | £0 | |
| Operating profit | £0 | £0 | |
| Profit before tax | £0 | £0 | |
| Net profit | £0 | £0 | |
| Cash | — | — | |
| Total assets less current liabilities | £47,039,000 | £47,039,000 | |
| Net assets | £47,039,000 | £47,039,000 | |
| Equity | £47,039,000 | £47,039,000 | |
| Average employees | — | — | |
| Wages | — | — | |
| Directors' remuneration | £0 | £0 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
—
Not reported
-
Cash
—
Not reported
-
Net assets
0%
£47,039,000 £47,039,000
-
Employees
—
Not reported
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Return on capital employed | 0.0% | 0.0% | |
| Current ratio | 14.11x | 14.11x |
Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 1 time since incorporation
- GENZYME THERAPEUTICS LIMITED 2001-12-21 → present
- TAYVIN 248 LIMITED 2001-11-05 → 2001-12-21
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- Forvis Mazars LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Material uncertainty disclosed
“As the company is no longer trading and the Directors intend to liquidate the company following the settlement of remaining net assets at a future date yet to be determined, they have prepared the financial statements on a basis other than going concern.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
2 active · 30 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| MOHAMED, Walaa Mostafa Abbas Awad | Director | 2026-02-01 | Oct 1977 | Egyptian |
| MOUSSA, Ahmed Mohamed Moustafa | Director | 2026-02-01 | Aug 1984 | Egyptian |
Show 30 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| BECKER, Marc | Secretary | 2006-05-26 | 2008-07-02 |
| DENNIS, Jonathan Charles | Secretary | 2008-07-02 | 2009-02-23 |
| DROHAN, Paul Victor | Secretary | 2005-11-04 | 2006-05-26 |
| FRANKLIN, Andrew Timothy | Secretary | 2011-06-01 | 2012-12-31 |
| FRENCH, David Allen | Secretary | 2009-02-23 | 2009-10-23 |
| HARROW, Terence Alfred, Dr | Secretary | 2003-11-04 | 2005-11-04 |
| KEANE, Antoinette | Secretary | 2013-01-24 | 2016-09-07 |
| SHORT, John Richard | Secretary | 2001-11-05 | 2003-11-04 |
| SMITH, Suzanne Elaine | Secretary | 2009-10-23 | 2011-04-30 |
| BAIRD, Jessamy Rachel | Director | 2022-10-01 | 2024-03-01 |
| COUSINS, Simon John, Dr | Director | 2003-11-04 | 2005-11-04 |
| DENNIS, Jonathan Charles | Director | 2008-07-02 | 2009-02-23 |
| DROHAN, Paul Victor | Director | 2005-11-04 | 2012-10-31 |
| DUHALDE, Francois-Xavier | Director | 2016-04-01 | 2021-03-31 |
| FARMER, Nicole Suzanne | Director | 2020-05-16 | 2022-10-01 |
| FRANKLIN, Andrew Timothy | Director | 2010-08-10 | 2012-12-31 |
| FULLER, David, Dr | Director | 2006-02-24 | 2007-09-04 |
| GOLDER, Quentin Robert | Director | 2001-11-05 | 2003-11-04 |
| HARRIS, Peter Anthony, Dr | Director | 2009-02-23 | 2012-06-30 |
| INCERTI, Carlo, Dr | Director | 2006-02-24 | 2011-09-15 |
| JOHNSON, Malcolm David | Director | 2003-11-04 | 2006-05-26 |
| KHAN, Usman | Director | 2021-03-31 | 2026-02-01 |
| KUIPER, Peter Sjoerd | Director | 2016-01-28 | 2020-05-16 |
| LENS, Willem Rutger | Director | 2006-02-24 | 2011-12-11 |
| MARTIN, Brendan James | Director | 2009-10-26 | 2016-01-28 |
| PROSSER, Andrew Michael James | Director | 2013-12-16 | 2016-04-01 |
| SHORT, John Richard | Director | 2001-11-05 | 2003-11-04 |
| SMITH, Alan, Dr | Director | 2006-02-24 | 2011-09-14 |
| UBHI, Rippondeep | Director | 2024-03-01 | 2026-02-01 |
| WYZGA, Michael | Director | 2006-02-24 | 2011-06-30 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Aventis Pharma Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2019-04-30 | Active |
| Sanofi-Aventis Uk Holdings Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Ceased 2019-04-30 |
Filing timeline
Last 20 of 133 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-02-05 | AP01 | officers | Appoint person director company with name date | |
| 2026-02-05 | TM01 | officers | Termination director company with name termination date | |
| 2026-02-05 | TM01 | officers | Termination director company with name termination date | |
| 2026-02-05 | AP01 | officers | Appoint person director company with name date | |
| 2026-01-05 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-12-12 | AA | accounts | Accounts with accounts type full | |
| 2025-05-27 | RP04AP01 | officers | Second filing of director appointment with name | |
| 2025-05-19 | CH01 | officers | Change person director company with change date | |
| 2025-02-09 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-07-06 | AA | accounts | Accounts with accounts type full | |
| 2024-03-03 | AP01 | officers | Appoint person director company with name date | |
| 2024-03-01 | TM01 | officers | Termination director company with name termination date | |
| 2024-02-02 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-07-18 | AA | accounts | Accounts with accounts type full | |
| 2023-01-06 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-10-14 | AP01 | officers | Appoint person director company with name date | |
| 2022-10-14 | TM01 | officers | Termination director company with name termination date | |
| 2022-07-15 | AA | accounts | Accounts with accounts type full | |
| 2022-02-07 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2021-07-28 | AA | accounts | Accounts with accounts type full |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 8
- Capital events
- 0
- Officers appointed
- 2
- Officers resigned
- 2
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.